Price Alert

Kiniksa Pharmaceuticals L... (KNSA)

NASDAQ: KNSA · Real-Time Price · USD

33.34

0.06 (0.18%)

At close: Aug 15, 2025, 2:57 PM

Kiniksa Pharmaceuticals Statistics

Share Statistics

Kiniksa Pharmaceuticals has 74.11M shares outstanding. The number of shares has increased by 2.42% in one year.

Shares Outstanding	74.11M
Shares Change (YoY)	2.42%
Shares Change (QoQ)	0.45%
Owned by Institutions (%)	53.36%
Shares Floating	70.88M
Failed to Deliver (FTD) Shares	1,082
FTD / Avg. Volume	0.14%

Short Selling Information

The latest short interest is 2.53M, so 3.47% of the outstanding shares have been sold short.

Short Interest	2.53M
Short % of Shares Out	3.47%
Short % of Float	6.51%
Short Ratio (days to cover)	4.26

Valuation Ratios

The PE ratio is -32.71 and the forward PE ratio is 19.3. Kiniksa Pharmaceuticals's PEG ratio is 0.08.

PE Ratio	-32.71
Forward PE	19.3
PS Ratio	3.34
Forward PS	3.1
PB Ratio	3.22
P/FCF Ratio	55.59
PEG Ratio	0.08

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Kiniksa Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.3, with a Debt / Equity ratio of 0.02.

Current Ratio	3.3
Quick Ratio	3.04
Debt / Equity	0.02
Debt / EBITDA	-0.22
Debt / FCF	0.39
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.34M
Profits Per Employee	$-137.12K
Employee Count	315
Asset Turnover	0.73
Inventory Turnover	2.31

Taxes

Income Tax	7.04M
Effective Tax Rate	-19.48%

Stock Price Statistics

The stock price has increased by 29.46% in the last 52 weeks. The beta is 0.13, so Kiniksa Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.13
52-Week Price Change	29.46%
50-Day Moving Average	28.93
200-Day Moving Average	23.67
Relative Strength Index (RSI)	62.82
Average Volume (20 Days)	796,848

Income Statement

In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.6.

Revenue	423.24M
Gross Profit	362.33M
Operating Income	-45.62M
Net Income	-43.19M
EBITDA	-45.62M
EBIT	-45.62M
Earnings Per Share (EPS)	-0.6

Full Income Statement

Balance Sheet

The company has 183.58M in cash and 9.86M in debt, giving a net cash position of 173.73M.

Cash & Cash Equivalents	183.58M
Total Debt	9.86M
Net Cash	173.73M
Retained Earnings	-521.14M
Total Assets	661.15M
Working Capital	302.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 25.69M and capital expenditures -277K, giving a free cash flow of 25.41M.

Operating Cash Flow	25.69M
Capital Expenditures	-277K
Free Cash Flow	25.41M
FCF Per Share	0.36

Full Cash Flow Statement

Margins

Gross margin is 85.61%, with operating and profit margins of -10.78% and -10.21%.

Gross Margin	85.61%
Operating Margin	-10.78%
Pretax Margin	-8.54%
Profit Margin	-10.21%
EBITDA Margin	-10.78%
EBIT Margin	-10.78%
FCF Margin	6%

Dividends & Yields

KNSA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for KNSA is $40, which is 22.2% higher than the current price. The consensus rating is "Buy".

Price Target	$40
Price Target Difference	22.2%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	8.84
Piotroski F-Score	5